Bayer Rebuffs Xarelto Sales Concern, Raises 2015 Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer raised its 2015 guidance on the back of expected strong growth for Xarelto and other recently launched products. The company said it is on track to divest its material science division by the first half of 2016 in order to become a pure-play life sciences company.